[NICE Guidance] Letermovir for preventing cytomegalovirus disease after a stem cell transplant

NICE |July 2019 | Letermovir for preventing cytomegalovirus disease after a stem cell transplant

NICE has today published final guidance which recommends the use of letermovir for the prevention of  cytomegalovirus reactivation and disease after allogeneic haematopoietic stem cell transplant in adults 

Read the full guidance from NICE

 

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s